Linked Life Data

18092152

Source:http://linkedlifedata.com/resource/pubmed/id/18092152

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-1-21
pubmed:abstractText
Accumulated data have shown the neuroactive properties of oxytocin (OT), a neurohypophyseal neuropeptide, and its capability of reducing the abuse potential of drugs. The present study investigated the effect of OT on methamphetamine (MAP)-induced hyperactivity in mice and its possible mechanism of action. Locomotor activity was measured after administered with MAP using an infrared sensor. High-performance liquid chromatography with electrochemical detection (HPLC-ECD) was used to detect the content of monoamines and their metabolites in the striatum and accumbens and prefrontal cortex in mice after the behavioral test. OT (0.1, 0.5, and 2.5 microg/mouse, i.c.v.) had no effect on locomotor activity in naïve mice, but inhibited, in a dose-dependent manner, the hyperactivity induced by acute administration of MAP. Atosiban (Ato) (2.0 microg/mouse, i.c.v.), the selective inhibitor of OT receptor, attenuated the inhibitory effect of OT on MAP. A marked reduction of the ratios of 3, 4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) to dopamine (DA) was observed in the striatum and accumbens of mice after acute administration of MAP. OT (2.5 microg, i.c.v.) significantly inhibited the reduction of DOPAC/DA and HVA/DA ratios. However, Ato decreased the ratio of DOPAC/DA significantly in mice compared with OT (2.5 microg) in combination with MAP. There was no significant change in serotonin (5-HT) metabolism in mice after a single administration of MAP. These results suggested that OT inhibited the MAP-induced hyperactivity by altering the DA turnover in the mesolimbic region of mice.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0028-1298
pubmed:author
pubmed:issnType
Print
pubmed:volume
376
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
441-8
pubmed:dateRevised
2008-9-3
pubmed:meshHeading
pubmed-meshheading:18092152-3,4-Dihydroxyphenylacetic Acid, pubmed-meshheading:18092152-Analysis of Variance, pubmed-meshheading:18092152-Animals, pubmed-meshheading:18092152-Behavior, Animal, pubmed-meshheading:18092152-Central Nervous System Stimulants, pubmed-meshheading:18092152-Cerebrum, pubmed-meshheading:18092152-Corpus Striatum, pubmed-meshheading:18092152-Dopamine, pubmed-meshheading:18092152-Dose-Response Relationship, Drug, pubmed-meshheading:18092152-Homovanillic Acid, pubmed-meshheading:18092152-Male, pubmed-meshheading:18092152-Methamphetamine, pubmed-meshheading:18092152-Mice, pubmed-meshheading:18092152-Motor Activity, pubmed-meshheading:18092152-Nucleus Accumbens, pubmed-meshheading:18092152-Oxytocin, pubmed-meshheading:18092152-Prefrontal Cortex, pubmed-meshheading:18092152-Receptors, Oxytocin, pubmed-meshheading:18092152-Serotonin, pubmed-meshheading:18092152-Vasotocin
pubmed:year
2008
pubmed:articleTitle
Inhibition by oxytocin of methamphetamine-induced hyperactivity related to dopamine turnover in the mesolimbic region in mice.
pubmed:affiliation
Department of Pharmacology, Shenyang Pharmaceutical University, 110016, Shenyang, People's Republic of China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't